Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital
Intelligence (DI) solutions for the public and private sectors,
announced today that proven industry veteran, Thomas E. Hogan has
been appointed Executive Chairman of the Board.
Based in Austin, Texas, Hogan brings a
remarkable 40+ year track record of exceptional shareholder
returns, client impact, and employee growth. He has significant
expertise in strategic M&A, sales and marketing, international
operations, and talent acquisition and development. During his
career Tom has led numerous acquisitions totally nearly $8B
including marquis targets such as Mercury Interactive and Opsware.
His career includes over a decade as both a private and publicly
held software CEO as well as senior executive posts ranging from
late stage private to mega-cap public companies.
“Tom’s experience will be invaluable as we scale
Cellebrite, extend our market leading digital intelligence
solutions, and ultimately enable justice across the globe. I am
excited to partner closely with Tom as we navigate our next chapter
of growth and global impact,” said Yossi Carmil, CEO,
Cellebrite.
“I look forward to my new partnership with
Yossi, Haim Shani and the entire Cellebrite board, and the talented
men and women across Cellebrite, as we build upon the impressive
momentum of the company. I am especially enthused about the
mission-driven purpose of this organization and our opportunity to
better equip law enforcement and judicial systems worldwide,” said
Thomas E. Hogan, Executive Chairman of the Board.
Hogan previously served as chairman and CEO of
Kony, Inc, President and CEO of Vignette (VIGN), executive vice
president of sales and marketing for Hewlett Packard, executive
vice president of software for HP, executive vice president of CSC,
chief sales officer at Siebel Systems, and most recently as a
Operating Managing Director at Vista Equity Partners. He has held
numerous public and private board positions including directorships
at Citrix, Gainsight, Pluralsight, Drift, Vignette, Kony, Vastera,
and Inforte. Tom holds a Masters in Management from Northwestern
University and a B.S. in Biomedical Engineering from the University
of Illinois.
Cellebrite’s current non-executive chairman,
Haim Shani, will remain an active member of the board. Haim will
leverage his extensive experience as the former CEO of NICE, the
former Director General of the Israel Ministry of Finance, and his
current role as founder and general manager of Israel Growth
Partners, to further strengthen contributions from the Cellebrite
board.
“On behalf of the entire Cellebrite board, I am
pleased to welcome Tom to the Cellebrite team. Getting to know Tom
as the head of the search committee and working with Yossi the past
four years, I believe their combined strengths deliver the best
leadership team in the industry. While I am passing the torch of
chairman duties to Tom, I will continue to contribute as an active
member of the Cellebrite board and look forward to working closely
with Tom and the Cellebrite management team as we continue our
journey,” said Haim Shani, former Cellebrite chairman.
About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable
its customers to protect and save lives, accelerate justice, and
preserve privacy in communities around the world. We are a global
leader in Digital Intelligence solutions for the public and private
sectors, empowering organizations in mastering the complexities of
legally sanctioned digital investigations by streamlining
intelligence processes.
Trusted by thousands of leading agencies and
companies worldwide, Cellebrite’s Digital Intelligence platform and
solutions transform how customers collect, review, analyze and
manage data in legally sanctioned investigations. To learn more
visit us
at www.cellebrite.com, https://investors.cellebrite.com,
or follow us on Twitter at @Cellebrite.
Caution Regarding Forward-Looking
Statements
This document includes “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the United States Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “forecast,” “intend,” “seek,” “target,” “anticipate,”
“believe,” “could,” “continue,” “expect,” “estimate,” “may,”
“plan,” “outlook,” “future” and “project” and other similar
expressions that predict, project or indicate future events or
trends or that are not statements of historical matters. Such
forward-looking statements include estimated financial information.
Such forward-looking statements with respect to revenues, earnings,
performance, strategies, prospects, and other aspects of the
business of Cellebrite are based on current expectations that are
subject to risks and uncertainties. A number of factors could cause
actual results or outcomes to differ materially from those
indicated by such forward-looking statements. These factors
include, but are not limited to: Cellebrite’s ability to develop
technologically advanced solutions and successfully integrate with
the software solutions used by customers; acceptance of solutions
by customers; errors, failures, defects or bugs in solutions; a
failure to maintain sales and marketing personnel productivity or
hire, integrate and retain additional sales and marketing
personnel; the impact of the global COVID-19 pandemic; the impact
of competition on pricing and on Cellebrite’s market share;
sub-optimal results from products due to misuse by customers;
Cellebrite’s failure to maintain and enhance its reputation and
brand; inaccuracy of the estimates of Cellebrite’s market
opportunity and forecasts of market growth; changes to packaging
and licensing models that adversely affect the ability to attract
or retain customers; failure to manage future growth effectively;
failure to introduce new solutions and add-ons; issues in the use
of artificial intelligence resulting in reputational harm or
liability; the need for additional capital to support the growth of
Cellebrite’s business; a failure to maintain the security of
operations and the integrity of software solutions; the impact of
government budgeting cycles and appropriations, early termination,
audits, investigations, sanctions and penalties; a decline in
government budgets, changes in spending or budgetary priorities, or
delays in contract awards; a failure to adequately obtain,
maintain, protect and enforce Cellebrite’s intellectual property or
infringement of the intellectual property rights of others;
perceptions or court or regulatory decisions that Cellebrite’s
solutions violate privacy rights; the use of solutions by customers
in a way that is, or that is perceived to be, incompatible with
human rights; failure to comply with laws regarding privacy, data
protection and security, technology protection, sanctions, export
controls and other matters; and other factors, risks and
uncertainties set forth in the sections titled “Risk Factors” and
“Cautionary Note Regarding Forward-Looking Statements” in our
Annual Report on form 20-F filed with the SEC on March 29, 2022 and
in other documents filed by Cellebrite with the U.S. Securities and
Exchange Commission (“SEC”), which are available free of charge at
www.sec.gov. You are cautioned not to place undue reliance upon any
forward-looking statements, which speak only as of the date made,
in this communication or elsewhere. Cellebrite undertakes no
obligation to update its forward-looking statements, whether as a
result of new information, future developments, or otherwise,
should circumstances change, except as otherwise required by
securities and other applicable laws.
Cellebrite Contacts
MediaVictor
CooperSr. Director of Corporate Communications +
Content
OperationsVictor.cooper@cellebrite.com+1
404.804.5910
InvestorsAndrew
KramerVP, Investor
RelationsInvestors@cellebrite.com+1
973.206.7760
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/774b7b9d-8b12-4bd0-9ff6-ad1b46feb3e0
Cellebrite Digital Intel... (NASDAQ:CLBTW)
過去 株価チャート
から 8 2024 まで 9 2024
Cellebrite Digital Intel... (NASDAQ:CLBTW)
過去 株価チャート
から 9 2023 まで 9 2024